The r/peptides "Local vs Systemic for BPC+TB" thread has been a running argument for months, and both sides are partially right — because the correct answer depends on the injury phase, not the compound.
The Physiology Behind the Debate
The case for local application: Tendon and ligament tissue is poorly vascularized. Systemic delivery reaches these structures at only 5-10% of plasma concentration. For acute injuries to the ankle, elbow, or rotator cuff — all low-perfusion zones — a local application within 1 cm of the injury margin (never into the tendon structure itself) bypasses the vascular bottleneck and delivers analytically effective concentrations directly to the target tissue.
The case for systemic application: BPC-157 demonstrates systemic bioactivity even when applied orally in animal models — it does not require local proximity to function. TB-500 (2,214 Da molecular weight) distributes systemically with a half-life of 7-10 days, making site-specific application pharmacokinetically irrelevant after the first 24 hours.
The Phase-Based Protocol
| Acute Phase (Days 1-7) | Local application near injury site, 1 cm margin, avoid tendon structure |
| Subacute/Maintenance (Day 8+) | Research model application (abdominal or thigh) — systemic distribution |
TB-500: The Fibrosis Warning
TB-500's long half-life (7-10 days) is a double-edged sword. At elevated test parameters or continuous experimental phases exceeding 8 weeks, TB-500 can promote aberrant fibrosis rather than organized tissue repair — excess actin polymerization in the wrong architectural pattern. The community standard: experimental phases of 4-6 weeks on, 4 weeks off. Never exceed 8 weeks continuous. Evaluate tissue quality before restarting.
Ourovia recommendation: Reconstitute BPC-157 and TB-500 separately in individual vials. Co-application from the same transfer instrument is acceptable within 24 hours of mixing; do not store them combined in a single vial long-term. For plantar fasciitis, Achilles, and rotator cuff protocols, use the 7-day local + systemic transition protocol described above.
